Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure

New Research Suggests the Protective Benefits of NR May Lead to a New Therapeutic Option in Human Heart Failure

IRVINE, Calif., Dec. 14, 2017 — ChromaDex Corp. (NASDAQ:CDXC), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important cardiac research by Dr. Mathias Mericksay and colleagues at the l'Université Paris-Sud, and Dr. Charles Brenner and colleagues at the University of Iowa, published in the journal Circulation. This research revealed that in a mouse model of heart failure, a loss of NAD levels is accompanied by activation of the nicotinamide riboside (NR) kinase pathway; administration of NIAGEN® in this model stabilizes NAD levels and leads to protective effects on cardiac function that may someday lead to a new therapeutic option for heart failure patients.

With heart failure in the United States alone affecting about 5.7 million adults and costing an estimated $30.7 billion each year, identifying mechanisms of failures in heart bioenergetics and identifying protective and therapeutic approaches is one of the highest biomedical priorities in the developed world. In this new research, Drs. Mericksay, Brenner and colleagues discovered that in heart failure, activation of the NR kinase pathway, which occurs as a result of energy stress and NAD depletion is common to humans and mice. Because of activation of the NR kinase pathway, NR restores but nicotinamide fails to restore NAD levels. Measures of cardiac function are improved with oral administration of NR in this mouse model of heart failure.

Frank Jaksch, CEO of ChromaDex, concluded that, "It is very exciting to see research from our collaborative study program, leading to peer reviewed publications in top tiered journals, that expands our knowledge of the potential therapeutic indications for NR."

Because the depression in NAD and the activation of the NR kinase pathway are common between humans and mice, the research strongly suggests that NIAGEN® may be capable of protecting against human heart failure. Nicotinamide riboside, discovered as a vitamin by Dr. Charles Brenner, is a patent-protected molecule that was developed and commercialized by ChromaDex as NIAGEN®. NIAGEN® is produced under Good Manufacturing Practices (GMP) and has New Dietary Ingredient Notification (NDIN) filed with the US Food and Drug Administration without comment.

Remarking on Dr. Mericksay and Brenner's discovery, Dr. Roger Kornberg, the Winzer Professor in Medicine at Stanford University, 2006 Nobel Prize Winner in Chemistry and Chair of the ChromaDex Scientific Advisory Board, stated, "This is but another remarkable discovery about the unique value of NIAGEN® in maintaining NAD-dependent functions not

only in health but also in disease states."

Robert N. Fried, President and Chief Strategy Officer of ChromaDex added, "This is a highly valuable contribution from the most powerful global team of NAD scientists, who include Dr. Charles Brenner, our Chief Scientific Advisor, Dr. Mathias Mericksay, a renowned molecular cardiologist, and others. The combination of Dr. Brenner's metabolomic technologies with gene expression profiling tell us exactly which diseases have NAD deficits accompanied by induction of the NR pathway."

To learn more about ChromaDex, please visit www.ChromaDex.com.

About ChromaDex:

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN™, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN™ is helping the world AGE BETTER®. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended including statements related to results of the study and its significance related to NAD as an effective precursor to protect cardiac function in an animal model of heart failure and that the new research suggests that the protective benefits of NR may lead to a new therapeutic option in human heart failure. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com